Therapeutic lifestyle changes and pharmaceutical care in the treatment of dyslipidemias in adults

Journal of the American Pharmacists Association

Volumn 45, Issue 4, 2005, Pages 492-502

  Lenz, Thomas L ^a  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dyslipidemias; Pharmaceutical care; Therapeutic lifestyle changes

Indexed keywords

ANTILIPEMIC AGENT;

ADULT; BEHAVIOR THERAPY; BODY WEIGHT; CONTROLLED STUDY; DRUG USE; DYSLIPIDEMIA; FAT INTAKE; HUMAN; LIFESTYLE MODIFICATION; MEDLINE; NUTRITIONAL ASSESSMENT; OBESITY; PHARMACEUTICAL CARE; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; REVIEW; EDUCATION; LIFESTYLE; PHARMACY; STANDARD;

ADULT; COMMUNITY PHARMACY SERVICES; DYSLIPIDEMIAS; EDUCATION, PHARMACY, CONTINUING; HUMANS; LIFE STYLE; PHARMACEUTICAL SERVICES; PRACTICE GUIDELINES;

EID: 33646932121     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/1544345054475595     Document Type: Review

References (50)

1. National Institutes of Health, National Heart, Lung, and Blood Institute. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Bethesda, Md.: National Institutes of Health; 2002. NIH publication 02-5215.
2. Grundy SM, Cleeman JI, Merz C, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel 111 guidelines. Circulation. 2004;110:227-39.
3. U.S. Department of Health and Human Services and U.S. Department of Agriculture. Dietary guidelines for Americans 2005. HHS publication. Accessed at http://healthierus.gov/dietaryguidelines, June 6, 2005.
4. American Heart Association Delicious Decision Web page. Accessed at www.deliciousdecisions.org, March 23, 2004.
5. Kris-Etherton PM, Yu S. Individual fatty acid effects on plasma lipids and lipoproteins: human studies. Am J Clin Nutr. 1997;65(suppl 5):1628S-1644S.
6. Mensink RP, Katan MB. Effects of dietary fatty acids on serum lipids and lipoproteins: a meta-analysis of 27 trials. Atherioscler Thromb. 1992;12:911-9.
7. Obarzanek E, Hunsberger SA, Van Horn L, et al. Safety of a fat-reduced diet: the Dietary Intervention Study in Children (DISC). Pediatrics. 1997;100:51-9.
8. Niinikoski H, Lapinleimu H, Viikari J, et al. Growth until three years of age in a prospective, randomized trial of a diet with reduced saturated fat and cholesterol. Pediatrics. 1997;99:687-94.
9. Lichtenstein AH, Ausman LM, Jalbert SM, Schaefer EJ. Effects of different forms of dietary hydrogenated fats on serum lipoprotein cholesterol levels. N Engl J Med. 1999;340:1933-40.
10. Judd JT, Clevidence BA, Muesing RA, et al. Dietary trans fatty acids: effects of plasma lipids and lipoproteins of healthy men and women. Am J Clin Nutr. 1994;59:861-8.
11. Judd JT, Baer DJ, Clevidence BA, et al. Effects of margarine compared with those of butter on blood lipid profiles related to cardiovascular disease risk factors in normolipemic adults fed controlled diets. Am J Clin Nutr. 1998;68:768-77.
12. Noakes M, Clifton PM. Oil blends containing partially hydrogenated or interesterified fats: differential effects on plasma lipids. Am J Clin Nutr. 1998;68:242-7.
13. Aro A, Jauhiainen M, Partanen R, et al. Stearic acid, trans-fatty acids, and dairy fat: effects on serum and lipoprotein lipids, apolopoprotiens, lipoprotein(a), and lipid transfer proteins in healthy subjects. Am J Clin Nutr. 1997;65:1419-26.
14. Almendingen K, Jordal O, Kierulf P, et al. Effects of partially hydrogenated fish oil, partially hydrogenated soybean oil, and butter on serum lipoproteins and Lp[a] in men. J Lipid Res. 1995;36:1370-84.
15. Wood R, Kubena K, O'Brien B, et al. Effect of butter, mono- and polyunsaturated fatty acid-enriched butter, trans-fatty acid margarine on serum lipids and lipoproteins in healthy men. J Lipid Res. 1993;34:1-11.
16. Wood R, Kubena K, Tseng S, et al. Effect of palm oil, margarine, butter, and sunflower oil on the serum lipids and lipoproteins of normo-cholesterolemic middle-aged men. J Nutr Biochem. 1993;4:286-97.
17. Nestel PJ, Noakes M, Belling GB, et al. Plasma cholesterol lowering potential of edible-oil blends suitable for commercial use. Am J Clin Nutr. 1992;55:46-50.
18. Zock PL, Katan MB. Hydrogenation alternatives: effects of trans fatty acids and stearic acid versus linoleic acid on serum lipids and lipoproteins in humans. J Lipid Res. 1992;33:399-410.
19. Katan MB, Zock, Mensink RP. Trans fatty acids and their effects on lipoproteins in humans. Annu Rev Nutr. 1995;15:473-93.
20. Mensink RP, Katan MB. Effects of dietary trans fatty acids on high density and low density lipoprotein cholesterol levels in healthy subjects. N Engl J Med. 1990;323:439-45.
21. Lichtenstein AH, Ausman LM, Carrasco W, et al. Hydrogenation impairs the hypolipidemic effect of corn oil in humans: hydrogenation, trans fatty acids, and plasma lipids. Arterioscler Thromb. 1993;13:154-61.
22. Willett WC, Stampfer MJ, Manson JE, et al. Intake of trans fatty acids and risk of coronary heart disease among women. Lancet. 1993;341:581-5.
23. Pietinen P, Ascherio A, Korhonen P, et al. Intake of fatty acids and risk of coronary heart disease in a cohort of Finnish men: the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Am J Epidemiol. 1997;145:876-87.
24. Hu FB, Stampfer MJ, Manson JE, et al. Dietary saturated fats and their food sources in relation to the risk of coronary heart disease in women. Am J Clin Nutr. 1999;70:1001-8.
25. Kromhout D, Menotti A, Bloemberg B, et al. Dietary saturated and trans fatty acids and cholesterol and 25 year mortality from coronary heart disease: the Seven Countries Study. Prev Med. 1995;24:308-15.
26. Tippett KS, Cleveland LE. How current diets stack up: comparison of dietary guidelines. In: America's eating habits: changes and consequences. Washington, D.C.: U.S. Dept. of Agriculture, Economic Research Service; 1999:51-70.
27. Putnam J, Gerrior S. Trends in the U.S. food supply, 1970-1997. In: America's eating habits: changes and consequences. Washington, D.C.: U.S. Dept. of Agriculture, Economic Research Service; 1999:133-60.
28. Grundy SM, Barrett-Conner E, Rudel LL, et al. Workshop on the impact of dietary cholesterol on plasma lipoproteins and atherogenesis. Arteriosclerosis. 1988;8:95-101.
29. National Research Council. Diet and health: implications for reducing chronic disease risk. Washington, D.C.: National Academy Press; 1989:171-201.
30. Westrate JA, Meijer GW. Plant sterol enriched margarines and reduction of plasma total and LDL cholesterol concentrations in normo-cholesterolaemic and mildly hypercholesterolaemic subjects. Eur J Clin Nutr. 1998;52:334-43.
31. Hallikainen MA, Uusitupa Ml. Effects of 2 low fat stanols ester containing margarines on serum cholesterol concentrations as part of a low fat diet in hypercholesterolaemic subjects. Am J Clin Nutr. 1999;69:403-10.
32. Gylling H, Miettinen TA. Cholesterol reduction by different plant stanols mixtures and with variable fat intake. Metabolism. 1999;48:575-80.
33. Gylling H, Radhakrishnan R, Miettinen TA. Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine: women in dietary sitostanol. Circulation. 1997;96:4226-31.
34. Hendriks HFJ, Weststrate JA, van Vliet T, Meijer GW. Spreads enriched with three different levels of vegetable oil sterols and the degree cholesterol lowering in normocholesterolaemic and mildly hypercholesterolaemic subjects. Eur J Clin Nutr. 1999;53:319-27.
35. Miettinen TA, Puska P, Gylling H, et al. Reduction of serum cholesterol with sitostanol ester margarine in a mildly hypercholesterolaemic population. N Engl J Med. 1995;333:1308-12.
36. Vanhanen HT, Blomqvist S, Ehnholm C, et al. Serum cholesterol, serum precursors, and plant sterols in hypercholesterolemic subjects with different apoE phenotypes during dietary sitostanol ester treatment. J Lipid Res. 1993;34:1535-44.
37. Vuorio AF, Gylling H, Turola H, et al. Stanol ester margarine alone with simvastatin lowers serum cholesterol in families with familial hypercholesterolemia caused by FH-North Karelia mutation. Arterio Thromb Vasc Biol. 2000;20:500-6.
38. Berke EM, Morden NE. Medical management of obesity. Am Fam Physicians. 2000;62:419-26.
39. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med. 2002;346:591-602.
40. Makdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes and obesity-related health risk factors, 2001. JAMA. 2003;289:76-9.
41. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Bethesda, Md.: National Institutes of Health; 1998. NIH publication 98-4083.
42. American College of Sports Medicine. ACSM's guidelines for exercise testing and prescription, 6th ed. New York: Lippincott Williams & Wilkins; 2000:3-32.
43. U.S. Dept. of Health and Human Services. Physical activity and health: a report of the Surgeon General. Atlanta: U.S. Dept. of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion; 1996.
44. Fletcher GF, Balady, G, Blair SN, et al. Statements on exercise: benefits and recommendations for physical activity programs for all Americans: a statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart Association. Circulation. 1996;94:857-62.
45. Centers for Disease Control and Prevention. Prevalence of physical activity, including lifestyle activities among adults-United States, 2000-2001. MMWR Morb Mort Wkly Rpt. 2003;52:764-9. Accessed at www.cdc.gov/mmwr/preview/ mmwrhtml/mm5232a2.htm, March 23, 2004.
46. Durstine JL, Moore GE. ACSM's exercise management for persons with chronic diseases and disabilities. Champaign, III.: Human Kinetics; 2003:142-3.
47. Pearson T, Kopin L Bridging the treatment gap: improving compliance with lipid-modifying agents and therapeutic lifestyle changes. Prev Cardiol. 2003;6:204-13.
48. American Pharmacists Association Web site. Accessed at www.aphanet.org/AM/Template.cfm?Section=Search&template=/CM/HTMLDisplay. cfm&ContentlD=2906, June 1, 2005.
49. Knapp KK, Paavola FG, Maine LL, et al. Availability of primary care providers and pharmacists in the United States. J Am Pharm Assoc. 1999;39:127-35.
50. Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in project ImPACT: hyperlipidemia. J Am Pharm Assoc. 2000;40:157-65.